Olaparib

AstraZeneca: Exciting ROpel Phase III trial results demonstrate the potential for Lynparza with abiraterone to become a new 1st-line option for patients with metastatic castration-resistant prostate cancer

(PRESS RELEASE) CAMBRIDGE, 24-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced positive…

3 years ago

AstraZeneca and Merck & Co., Inc. announce positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets

Lynparza met primary endpoint of progression-free survival in women with BRCA-mutated advanced ovarian cancer and showed a safety profile consistent…

6 years ago

AstraZeneca, Voluntis, US National Cancer Institute to test companion mobile app in ovarian cancer studies

LONDON, 10-12-2015 — /EuropaWire/ — AstraZeneca today announced plans to test a digital support service for women undergoing treatment for…

8 years ago

AstraZeneca, University of Cambridge and Cancer Research UK partner on 3 pre-clinical and clinical oncology projects

16-7-2013 — /europawire.eu/ — AstraZeneca today announced that it has entered into an agreement with the University of Cambridge and Cancer…

11 years ago